Sarepta Therapeutics (SRPT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting called to order at 10:00 A.M. Eastern Time, with agenda available in the webcast documents.
Attendees instructed on how to submit questions relevant to the meeting.
Board and executive committee updates
Full Board of Directors and executive committee members introduced, including CEO, CFO, and other key officers.
KPMG representatives and Computershare appointed as Inspector of Election present.
Shareholder proposals
No additional shareholder proposals were introduced as none were received per bylaws.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Sarepta Therapeutics
- Strong financials and pipeline progress drive confidence in growth and regulatory stability.SRPT
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Q1 2026 delivered strong profitability, positive cash flow, and reaffirmed FY 2026 guidance.SRPTQ1 20267 May 2026
- Proxy seeks approval for director elections, compensation, equity plans, and auditor ratification.SRPTProxy filing24 Apr 2026
- Virtual annual meeting on June 4, 2026, includes key votes on directors, pay, and auditor.SRPTProxy filing24 Apr 2026
- 2026 outlook: $954M cash, $1.2–$1.4B revenue guidance, stable franchises, Japan launch.SRPTQ4 202512 Apr 2026
- SRP-1001 and SRP-1003 show strong early efficacy, safety, and muscle delivery, with phase III trials planned for 2027.SRPTStudy result25 Mar 2026
- 2026 revenue targets remain solid as clinical and commercial initiatives advance toward 2027.SRPTTD Cowen 46th Annual Health Care Conference3 Mar 2026
- Two-year results confirm durable efficacy, safety, and muscle health benefits in Duchenne.SRPTStatus Update3 Feb 2026
- FDA expands ELEVIDYS approval for Duchenne patients 4+, with robust readiness and stable pricing.SRPTStatus Update3 Feb 2026